Diamedica Therapeutics Inc (DMAC)
EBITDA Growth
-31.60%
Quarterly · Period ending:
DMAC EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-31.60%period ending
Latest reported-31.60%period ending
DMAC Quarterly EBITDA YoY % (-53.61% → -31.60%)
Year-over-year change
High-resolution chart · PNG
DMAC ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -31.5995% | |
| -30.3511% | |
| -10.6472% | |
| -37.3821% | |
| -50.7252% | |
| -49.7274% | |
| -53.5763% | |
| -40.4174% | |
| -14.3177% | |
| 2.3203% | |
| -43.3641% | |
| -46.3383% | |
| -33.423% | |
| -50.4435% | |
| -10.7021% | |
| 11.4053% | |
| -2.5759% | |
| 3.266% | |
| 24.1614% | |
| -4.4998% | |
| -23.6164% | |
| -58.2567% | |
| -4.8708% | |
| -37.4425% | |
| -5.0996% | |
| 29.4717% | |
| -132.0205% | |
| -61.3621% | |
| -35.8225% | |
| -463.5112% | |
| -97.3664% | |
| -106.1305% | |
| -74.5062% | |
| 55.4593% | |
| -126.0675% | |
| 22.5419% | |
| -110.7208% | |
| -313.8305% | |
| 16.1249% | |
| -370.0162% | |
| -51.1978% | |
| 28.5266% | |
| 38.8197% | |
| 77.6143% | |
| 73.3614% | |
| 78.3731% | |
| 35.4941% | |
| 31.4617% | |
| 24.3417% | |
| 5.6051% | |
| 51.2503% | |
| 34.1549% | |
| 16.3936% | |
| -70.6643% | |
| -90.8283% | |
| -52.9683% | |
| -115.1045% | |
| -23.7342% | |
| -439.9627% | |
| -263.8671% | |
| -46.3215% | |
| -164.7257% | |
| 52.7012% | |
| 38.1951% | |
| -38.536% | |
| 37.442% | |
| -119.3506% | |
| 15.6429% | |
| 27.0418% | |
| -42.9833% | |
| 63.0677% | |
| -77.5618% | |
| 38.7452% | |
| -154.586% | |
| -208.618% | |
| -94.9499% | |
| -33,939.4451% | |
| -5,968.5547% | |
| -278.0754% | |
| -270.2452% | |
| 105.9929% | |
| -53.6144% |